Skip to main content

ZYNEX INC

corporate_fare Company Profile

ZYNEX INC

ZYXIQ·OTC·Industrial Applications And Services·CIK 0000846475

Zynex, Inc. is a medical technology company that designs, manufactures, and markets medical devices. The company was founded in 1996 by Thomas Sandgaard and is the parent company of two active subsidiaries: Zynex Medical, Inc. (ZMI) and Zynex Monitoring Solutions, Inc. (ZMS). Substantially all of the company's consolidated revenue in 2024 and 2023 was attributable to ZMI. Zynex, Inc. is headquartered in Englewood, Colorado. Zynex Medical, Inc. (ZMI) focuses on medical devices for treating chronic and acute pain, and for activating and exercising muscles for rehabilitation using electrical stimulation. These devices aim to manage pain, reduce reliance on medications, and improve mobility through non-invasive muscle stimulation, electromyography technology, interferential current (IFC), neuromuscular electrical stimulation (NMES), and transcutaneous electrical nerve stimulation (TENS). All medical devices are designed for patient-friendly home use, are small, portable, battery-operated, and include an electrical pulse generator connected to the body via electrodes. These devices are marketed in the U.S., are subject to FDA regulation and clearance, and require a physician's prescription. The primary product is the NexWave device, marketed to physicians and therapists by field sales representatives. The NexWave requires consumable supplies like electrodes and batteries, which are shipped to patients as needed. ZMI also distributes private labeled rehabilitation products, including back, knee, and wrist braces, cervical and lumbar traction, and hot/cold therapy. These products complement the pain management offerings, require a prescription, and are covered by most insurance plans and Medicare. ZMI also designs, manufactures, and markets the NeuroMove product.

ZYNEX INC (OTC:ZYXIQ) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 8 items for ZYXIQ at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-03-26, rated 10/10. Across its 8 most recent items scored 7 or higher, the top rating is 10/10, with 8 rated 8 or above. Recent SEC coverage for ZYXIQ spans 8-K.

Recent high-impact activity:

  • Zynex Emerges from Chapter 11; All Existing Equity Cancelled, New Control Established
  • Bankruptcy Court Confirms Reorganization Plan, Cancelling All Existing Common Stock
  • SEC Concludes Investigation into Zynex Without Recommending Enforcement Action
  • Zynex Resolves Federal Fraud Investigation with Non-Prosecution Agreement, Paving Way for Chapter 11 Exit
  • Zynex Files Third Amended Chapter 11 Plan, Sets Voting Deadline

No longer listed

ZYXIQ (ZYNEX INC) is no longer listed on a major US exchange, so Wiseek no longer shows market data for this symbol. It last appeared on NASDAQ. The filings and coverage below remain available as an archive.

feed ZYXIQ - Latest Insights

ZYXIQ
Mar 26, 2026, 5:02 PM EDT
Filing Type: 8-K
Importance Score:
10
ZYXIQ
Mar 20, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
10
ZYXIQ
Feb 19, 2026, 4:22 PM EST
Filing Type: 8-K
Importance Score:
8
ZYXIQ
Feb 18, 2026, 4:37 PM EST
Filing Type: 8-K
Importance Score:
9
ZYXIQ
Feb 11, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
8
ZYXIQ
Feb 02, 2026, 4:28 PM EST
Filing Type: 8-K
Importance Score:
9
ZYXIQ
Jan 23, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
9
ZYXIQ
Jan 15, 2026, 4:35 PM EST
Filing Type: 8-K
Importance Score:
10
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets